Table 2.
Haplogroup distribution of European non-Ashkenazi Jewish (Seph) T2DM patients who developed complications and the "No complications" group as in table 1. Patients included in this table may have more than one complication.
| Haplogroup | All Seph n (%) | No complication n (%) | Cardiovascular n (%) | Retino-pathy n (%) | Nephro-pathy n (%) |
| U (nonK) | 12 (6.5) | 5 (7.7) | 3 (5.4) | 1 (2.7) | 5 (7.7) |
| K | 21 (11.3) | 6 (9.2) | 7 (12.5) | 7 (18.9) | 9 (13.8) |
| 1HV* | 17 (9.1) | 4 (6.2) | 5 (8.9) | 7 (18.9) | 10 (15.4) |
| H | 49 (26.3) | 17 (26.2) | 16 (28.6) | 6 (16.2) | 14 (21.5) |
| J1** | 16 (8.6) | 5 (7.7) | 3 (5.4) | 4 (10.8) | 8 (12.3) |
| T | 26 (14) | 12 (18.5) | 7 (12.5) | 4 (10.8) | 4 (6.2) |
| N1b | 7 (3.8) | 2 (3.1) | 2 (3.6) | 2 (5.4) | 3 (4.6) |
| WXI | 12 (6.5) | 4 (6.2) | 3 (5.4) | 3 (8.1) | 3 (4.6) |
| 2Others | 26 (14) | 10 (15.4) | 10 (17.6) | 3 (8.1) | 9 (13.8) |
| Total | 186 | 65 | 56 | 37 | 65 |
1HV* – see table 1. 2Others – see table 1. **After removing the J2 patients (see Materials and Methods), we were left only with J1 patients; thus, the sample size was reduced from 191 to 186 for the total population and the complications groups were adjusted accordingly.